124012 Akt Inhibitor V, Triciribine - CAS 35943-35-2 - Calbiochem

124012
Árak és elérhetőség megtekintése

Áttekintés

Replacement Information

Kulcsspecifikációk táblázata

Empirical FormulaCAS #
C₁₃H₁₆N₆O₄ 35943-35-2

Árak és elérhetőség

Katalógusszám ElérhetőségCsomagolás Menny./csomag Ár Mennyiség
124012-10MG
Elérhetőség betöltése...
Korlátozott elérhetőségKorlátozott elérhetőség
Készleten 
Megszűnt
Korlátozott mennyiségben elérhető
Az elérhetőség megerősítésre vár
    Remaining : Will advise
      Remaining : Will advise
      Tanácsadás
      Lépjen kapcsolatba a vevőszolgálattal
      Contact Customer Service

      Üvegpalack 10 mg
      Az ár letöltése folyamatban...
      Az ár nem tölthető be
      Minimum Quantity needs to be mulitiple of
      Megrendelés befejezésekor További információ
      Elmentette a ()-t
       
      Árajánlat kérése
      124012-1MG
      Elérhetőség betöltése...
      Korlátozott elérhetőségKorlátozott elérhetőség
      Készleten 
      Megszűnt
      Korlátozott mennyiségben elérhető
      Az elérhetőség megerősítésre vár
        Remaining : Will advise
          Remaining : Will advise
          Tanácsadás
          Lépjen kapcsolatba a vevőszolgálattal
          Contact Customer Service

          Muanyagampulla 1 mg
          Az ár letöltése folyamatban...
          Az ár nem tölthető be
          Minimum Quantity needs to be mulitiple of
          Megrendelés befejezésekor További információ
          Elmentette a ()-t
           
          Árajánlat kérése
          Description
          OverviewA cell-permeable and reversible tricyclic nucleoside that selectively inhibits the cellular phosphorylation/activation of Akt1/2/3. It does not inhibit known upstream activators of Akt, i.e. PI3K or PDK. Exhibits little effect towards cellular signaling pathways mediated by PKC, PKA, SGK, Stat3, p38, ERK1/2, or JNK. Shown to preferentially induce apoptosis and growth arrest in cancer cells with aberrant Akt activity both in vitro (≥ 60% in cell proliferation at 20 µM) and in vivo (≥ 80% inhibition in tumor growth in mice at 1 mg/kg/day, i.p.). Also available in InSolution™ format (Cat. No. 124038).
          Catalogue Number124012
          Brand Family Calbiochem®
          SynonymsNSC 154020, TCN, Akt/PKB Signaling Inhibitor-2, API-2
          References
          ReferencesKarst, A., et al. 2006. Cancer Res. 66, 9225.
          Yang, L., et al. 2004. Cancer Res. 64, 4394.
          Product Information
          CAS number35943-35-2
          ATP CompetitiveN
          FormSolid
          Hill FormulaC₁₃H₁₆N₆O₄
          Chemical formulaC₁₃H₁₆N₆O₄
          ReversibleY
          Structure formula ImageStructure formula Image
          Quality LevelMQ100
          Applications
          ApplicationAkt Inhibitor V, Triciribine, CAS 35943-35-2, is a cell-permeable, selective, reversible inhibitor of the cellular phosphorylation/activation of Akt1/2/3.
          Biological Information
          Primary TargetAkt1, Akt 2, Akt3
          Purity≥95% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          RTECSRY8455000
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Carcinogenic / Teratogenic
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Akt Inhibitor V, Triciribine - CAS 35943-35-2 - Calbiochem MSDS

          Title

          Safety Data Sheet (SDS) 

          Akt Inhibitor V, Triciribine - CAS 35943-35-2 - Calbiochem Certificates of Analysis

          TitleLot Number
          124012

          References

          Hivatkozások áttekintése
          Karst, A., et al. 2006. Cancer Res. 66, 9225.
          Yang, L., et al. 2004. Cancer Res. 64, 4394.

          Brochure

          Title
          Akt
          Biologics 31.1
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision16-January-2012 RFH
          SynonymsNSC 154020, TCN, Akt/PKB Signaling Inhibitor-2, API-2
          DescriptionA cell-permeable and reversible tricyclic nucleoside that selectively inhibits the cellular phosphorylation/activation of Akt1/2/3 by targeting an Akt effector molecule other than PI 3-K or PDK. Exhibits little effect towards cellular signaling pathways mediated by PKC, PKA, SGK, Stat3, p38, ERK1/2, or JNK. Shown to preferentially induce apoptosis and growth arrest in cancer cells with aberrant Akt activity both in vitro (≥60% in cell proliferation at 20 µM) and in vivo (≥80% inhibition in tumor growth in mice at 1 mg/kg/day, i.p.). Also available in InSolution™ format (Cat. No. 124038.
          FormSolid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number35943-35-2
          RTECSRY8455000
          Chemical formulaC₁₃H₁₆N₆O₄
          Structure formulaStructure formula
          Purity≥95% by HPLC
          SolubilityDMSO (10 mg/ml). Further dilute at aqueous buffer in low micromolar concentrations.
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Toxicity Carcinogenic / Teratogenic
          ReferencesKarst, A., et al. 2006. Cancer Res. 66, 9225.
          Yang, L., et al. 2004. Cancer Res. 64, 4394.